SECTOR : Biotech
ENTRY DATE : 2019
BUSINESS : Venture Capital
WEB : agomab.com
Modulating regenerative pathways to restore organ function
Loss of tissue functionality or organ failure is often a result of inflammatory, metabolic, and fibrotic processes which can occur in a variety of difficult-to-treat diseases. AgomAb aims to resolve these processes by modulating specific regenerative pathways in the target tissue or throughout the body, ultimately leading to a structural repair of tissue and the restoration of organ function.
PRESS RELEASE :
03/04/2019 • AgomAb Therapeutics Completes Euros 21m Series A Financing